Most of the Effect of Paroxetine for Treating Hot Flashes May Be Placebo Effect
TUESDAY, Sept. 5, 2023 -- Most of the efficacy of paroxetine to treat hot flashes may be a placebo effect, according to a review published online Aug. 4 in Frontiers in Psychiatry. Joshua R. Rhodes, Ph.D., from Abilene Christian University in Texas,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 5, 2023 Category: Pharmaceuticals Source Type: news
The effects of paroxetine therapy on depressive symptom and motor function in the treatment of depression with Parkinson's disease: a meta-analysis - Jiang LL, Wu YL, Mo Y, Gou L, Chen ML, Wang Y, Zang QM, Jiang DQ.
BACKGROUND: Paroxetine therapy has been used for treatment of patients with depression and Parkinson's disease (dPD) in many clinical studies, but, the effects of paroxetine in dPD patients are not completely understood. The aim of this study was to system... (Source: SafetyLit)
Source: SafetyLit - September 4, 2023 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Most antidepressants prescribed for chronic pain lack reliable evidence of efficacy or safety, scientists warn
Largest ever investigation into antidepressants used for chronic pain shows insufficient evidence to determine how effective or harmful they may be.Study reviewed commonly prescribed medications including amitriptyline, duloxetine, fluoxetine, citalopram, paroxetine, and sertraline.One third of people globally are living with long-term pain with many prescribed antidepressants to relieve symptoms.Most antidepressants used for chronic pain are being prescribed with “insufficient” evidence of their effectiveness, scientists have warned.A major investigation into medications used to manage long-term pain found that harms ...
Source: Cochrane News and Events - May 9, 2023 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Antidepressant discontinuation syndrome resulting in a suicide attempt: a case report - Waldvogel N, Akira A.
Antidepressant discontinuation syndrome (ADS) is a common complication of abrupt cessation or inadequate tapering of antidepressants. In one randomized controlled trial,1 abrupt paroxetine discontinuation resulted in withdrawal symptoms in 34.5% of patient... (Source: SafetyLit)
Source: SafetyLit - October 18, 2022 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
Attempted "suicide by police" by a patient with bipolar I disorder and PTSD on paroxetine monotherapy - Condiotte A, Govada V.
Bipolar disorder affects approximately 50 million individuals worldwide1 and is associated with a significant burden of disability, with a high rate of delayed or misdiagnosis and low rates of appropriate treatment.2,3 Among those diagnosed with bipolar di... (Source: SafetyLit)
Source: SafetyLit - May 30, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Class 2 Medicines Recall: Crescent Pharma Limited, Paroxetine 40mg Film Coated Tablets
Crescent Pharma Limited are recalling a specific batch of Paroxetine 40mg Film Coated Tablets as a precautionary measure due to out of specification results for dissolution during routine stability te (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - April 27, 2022 Category: Drugs & Pharmacology Source Type: news
Paroxetine overdose during pregnancy - Acar S, Erol H, Arslan EK, Uysal N, Karada ş B, Temiz TK, Cem Kaplan Y.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression and anxiety disorders. In some epidemiological studies, slightly increased risks of major malformations and cardiac malformations have been reported following... (Source: SafetyLit)
Source: SafetyLit - December 8, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Patient and clinical factors associated with response to medications for posttraumatic stress disorder - Shiner BR, Gui J, Rozema L, Cornelius SL, Dufort V, Schnurr PP, Watts BV.
OBJECTIVE: Fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine have previously shown efficacy for posttraumatic stress disorder (PTSD) in randomized clinical trials. Two prior studies using Department of Veterans Affairs (VA) medical records da... (Source: SafetyLit)
Source: SafetyLit - October 11, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Dr Reddy's, Zydus Pharma recall products in US market
As per the report by the USFDA, Zydus Pharmaceuticals (USA) Inc, is recalling 2,880 bottles of Carvedilol tablets, USP 25 mg in the US due to, "presence of foreign tablets/ capsules; report of two Paroxetine tablets were found in the bottle." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 29, 2021 Category: Pharmaceuticals Source Type: news
Predictors and trajectories of treatment response to SSRIs in patients suffering from PTSD - N øhr AK, Eriksson H, Hobart M, Moltke I, Buller R, Albrechtsen A, Lindgreen S.
We examined predictors and latent classes of SS... (Source: SafetyLit)
Source: SafetyLit - May 13, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
A New Study Points to MDMA as a Powerful Treatment for PTSD
Post-Traumatic Stress Disorder (PTSD), will affect some 26 million Americans at some point in their lives, according to the Department of Veterans Affairs. The condition, characterized by depression, hopelessness, memory problems, difficulty maintaining relationships, and recurrent visions of the trauma-causing event is notoriously hard to treat. Up to a third of people with the condition are still symptomatic 10 years after diagnosis, and the main therapeutic drugs of choice—the selective serotonin reuptake inhibitors sertraline and paroxetine—fail in up to 60% of patients. A study published yesterday, however...
Source: TIME: Health - May 11, 2021 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized Source Type: news
What Helps With Paxil Withdrawal?
Title: What Helps With Paxil Withdrawal?Category: Diseases and ConditionsCreated: 12/31/2020 12:00:00 AMLast Editorial Review: 12/31/2020 12:00:00 AM (Source: MedicineNet Depression General)
Source: MedicineNet Depression General - December 31, 2020 Category: Psychiatry Source Type: news
Model May Help Predict Risk for Testing Positive for COVID - 19
Risk reduced with pneumococcal polysaccharide, flu vaccine; melatonin, paroxetine, or carvedilol use (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 25, 2020 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Critical Care, Emergency Medicine, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news
Paroxetine (marketed as Paxil) Information
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 2, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Drug Supply issue: Seroxat (paroxetine) 20mg/10ml oral solution
The Department of Health and Social Care (DHSC) has issued information about supply issues affecting paroxetine 20mg/10ml oral solution. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 25, 2019 Category: Drugs & Pharmacology Source Type: news